Accès gratuit
Numéro
Med Sci (Paris)
Volume 22, Numéro 4, Avril 2006
Page(s) 416 - 422
Section M/S revues
DOI https://doi.org/10.1051/medsci/2006224416
Publié en ligne 15 avril 2006
  1. Lotersztajn S. Les endothélines. Med Sci (Paris) 1993; 9 : 1084–93.
  2. Cazaubon S, Couraud PO. Nitric oxide and endothelin at the blood-brain barrier. In : Pardrige W, ed. Introduction to the blood-brain barrier. New York Raven Press Ltd, 1998 : 338–44.
  3. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 2000; 11 : 1–6.
  4. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1 : 944–9.
  5. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis : emerging role in cancer. Nat Rev Cancer 2003; 3 : 110–6.
  6. Grant K, Loizidou M, Taylor I. Endothelin-1 : a multifunctional molecule in cancer. Br J Cancer 2003; 88 : 163–6.
  7. Deshayes F, Nahmias C. Angiotensin II receptors : a new role in cancer ? Trends Endocrinol Metab 2005; 16 : 293–9.
  8. Egidy G, Baviera E, Ciuffo G, et al. Localization of the endothelin system in aldosterone-producing adenomas. Hypertension 2001; 38 : 1137–42.
  9. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004; 90 : 1059–68.
  10. Anguelova E, Beuvon F, Leonard N, et al. Functional endothelin ET(B) receptors are selectively expressed in human oligodendrogliomas. Brain Res Mol Brain Res 2005; 137 : 77–88.
  11. Lazarini F, Strosberg AD, Couraud PO, Cazaubon SM. Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes. J Neurochem 1996; 66 : 459–65.
  12. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999; 96 : 11496–500.
  13. Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res 2001; 89 : 1138–46.
  14. Boivin B, Chevalier D, Villeneuve LR, et al. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 2003; 278 : 29153–63.
  15. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112 : 67–75.
  16. Fujita M, Hayashi I, Yamashina S, et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005; 26 : 271–9.
  17. Arrieta O, Guevara P, Escobar E, et al. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 2005; 92 : 1247–52.
  18. Fischer O, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003; 31 : 1203–8.
  19. Elbaz N, Bedecs K, Masson M, et al. Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor. Mol Endocrinol 2000; 14 : 795–804.
  20. Nouet S, Amzallag N, Li J, et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 2004; 279 : 28989–97.
  21. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003; 14 : 44–50.
  22. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator : biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2 : 385–99.
  23. Rosano L, Spinella F, Di Castro V, et al. Endothelin receptor blockade inhibits molecular effectors of Kaposi’s sarcoma cell invasion and tumor growth in vivo. Am J Pathol 2003; 163 : 753–62.
  24. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100 : 10954–9.
  25. Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000; 83 : 360–5.
  26. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98 : 671–9.
  27. Prontera C, Mariani B, Rossi C, et al. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999; 81 : 761–6.
  28. Lindberg H, Nielsen D, Jensen B, et al. Angiotensin converting enzyme inhibitors for cancer treatment ? Acta Oncol 2004; 43 : 142–52.
  29. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62 : 4176–9.
  30. Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294 : 441–7.
  31. Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005; 11 : 2686–94.
  32. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer : a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21 : 679–89.
  33. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas : safety and pharmacokinetics. J Clin Oncol 2002; 20 : 2171–80.
  34. Lever A, Hole D, Gillis C, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer ? Lancet 1998; 352 : 179–84.
  35. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer : a population-based cohort study in Denmark. Cancer 2001; 92 : 2462–70.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.